NASDAQ:RDUS

Radius Health Stock Forecast, Price & News

$13.56

+0.29 (+2.19 %)

(As of 10/22/2020 12:00 AM ET)

Add

Compare

Today's Range

$12.63

Now: $13.56▼

$13.69

50-Day Range

$10.80

MA: $12.23▼

$13.86

52-Week Range

$10.15

Now: $13.56▼

$29.89

Volume414,423 shs

Average Volume599,375 shs

Market Capitalization$630.16 million

P/E RatioN/A

Dividend YieldN/A

Beta1.07

Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Beat the Market (BTM) Rank^™

4.1 Analyst's Opinion

Consensus Rating
Radius Health has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.50, Radius Health has a forecasted upside of 58.6% from its current price of $13.56.
Amount of Analyst Coverage
Radius Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
Radius Health has received 502 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Radius Health has received 409 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Radius Health has received 55.10% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote “Outperform” if you believe RDUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Radius Health does not currently pay a dividend.
Dividend Growth
Radius Health does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Radius Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,592,999.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.92% of the stock of Radius Health is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Radius Health are expected to grow in the coming year, from ($2.42) to ($1.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Radius Health is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Radius Health is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

2.10 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:RDUS

Previous Symbol

CUSIPN/A

CIK1428522

Webwww.radiuspharm.com

Phone617-551-4000

Employees398

Debt

Debt-to-Equity RatioN/A

Current Ratio2.43

Quick Ratio2.35

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$173.32 million

Price / Sales3.64

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.92) per share

Price / Book-14.74

Profitability

EPS (Most Recent Fiscal Year)($2.89)

Net Income$-132,990,000.00

Net Margins-67.99%

Return on EquityN/A

Return on Assets-66.22%

Miscellaneous

Outstanding Shares46,472,000

Market Cap$630.16 million

Next Earnings Date11/5/2020 (Confirmed)

OptionableOptionable

$13.56

+0.29 (+2.19 %)

(As of 10/22/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

How has Radius Health's stock price been impacted by Coronavirus?

Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RDUS stock has decreased by 15.6% and is now trading at $13.56.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Radius Health?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Radius Health.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Radius Health.

How can I listen to Radius Health's earnings call?

Radius Health will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) announced its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.82) by $0.13. The biopharmaceutical company earned $50.11 million during the quarter, compared to analysts' expectations of $48.43 million.
View Radius Health's earnings history.

What price target have analysts set for RDUS?

8 equities research analysts have issued 1 year price objectives for Radius Health's stock. Their forecasts range from $14.00 to $27.00. On average, they expect Radius Health's stock price to reach $21.50 in the next year. This suggests a possible upside of 58.6% from the stock's current price.
View analysts' price targets for Radius Health.

Who are some of Radius Health's key competitors?

Some companies that are related to Radius Health include Harmony Biosciences (HRMY), Pacira Biosciences (PCRX), I-Mab (IMAB), Taro Pharmaceutical Industries (TARO), Xencor (XNCR), Aimmune Therapeutics (AIMT), Seres Therapeutics (MCRB), Karuna Therapeutics (KRTX), Corcept Therapeutics (CORT), Madrigal Pharmaceuticals (MDGL), Amarin (AMRN), Aurinia Pharmaceuticals (AUPH), Akcea Therapeutics (AKCA), uniQure (QURE) and Zymeworks (ZYME).
View all competitors.

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), Opko Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

Who are Radius Health's key executives?

Radius Health's management team includes the following people:

Mr. Jesper Høiland, Pres, CEO & Director (Age 59)
Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)
Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)
Mr. Brian Nicholas Harvey, Advisor (Age 58)
Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.38%) and Pacer Advisors Inc. (0.01%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, Target N V Biotech and Willard H Dere.
View institutional ownership trends for Radius Health.

Which institutional investors are buying Radius Health stock?

RDUS stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., and Pacer Advisors Inc.. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, and Target N V Biotech.
View insider buying and selling activity for Radius Health.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $13.56.

How big of a company is Radius Health?

Radius Health has a market capitalization of $630.16 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings